---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-005080"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T12:52:59.466680+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ionis Q4 rev $227M, FY rev $705M; 2025 guidance rev >$600M, non-GAAP op loss <$495M

## Summary
- FY2024 total revenue $705M exceeded guidance; operating loss $475M GAAP, $345M non-GAAP.
- WAINUA launched Jan 2024: $85M product sales, $20M royalties; 84% QoQ growth in Q4.
- TRYNGOLZA approved Dec 19, 2024 for FCS; first independent launch underway.
- Donidalorsen PDUFA date Aug 21, 2025 for HAE; OLE data shows 96% sustained mean attack rate reduction.
- 2025 guidance: revenue >$600M, non-GAAP op loss <$495M, cash ~$1.7B.

## SEC filing metadata
- accession: 0001140361-25-005080
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036125005080/0001140361-25-005080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036125005080/ef20043828_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-005080
- JSON: https://secwatch.observer/filing/0001140361-25-005080.json
- Plain text: https://secwatch.observer/filing/0001140361-25-005080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.